Vlad Coric talks about the pipeline 'New Biohaven' has in motion after Pfizer's acquisition of its CGRPs

Jan 7, 2024
1 min read

He discusses protein degradation, KV7 ion channel modulation, myostatin inhibition for obesity, and more.

Recent Posts

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

Vlad Coric talks about the pipeline 'New Biohaven' has in motion after Pfizer's acquisition of its CGRPs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight